Metabolomics in multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 4, 2016, Pages 451-460

  Bhargava, Pavan ^a   Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; mass spectrometry; Metabolomics; multiple sclerosis; nuclear magnetic resonance

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; ARGININE; ASPARAGINE; ASPARTIC ACID; BIOLOGICAL MARKER; BRANCHED CHAIN AMINO ACID; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; ORNITHINE; PHOSPHOETHANOLAMINE; PUTRESCINE; TAURINE; BILE ACID;

CEREBROSPINAL FLUID ANALYSIS; EXPERIMENTAL ALLERGIC ENCEPHALITIS; GENOMICS; HUMAN; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERSONALIZED MEDICINE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ANALYSIS; PROTEIN TARGETING; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; ANIMAL; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; WORKFLOW; BIOINFORMATICS; EXPERIMENTAL DESIGN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLITE; NEUROLOGIC DISEASE; URINE BIOCHEMISTRY;

ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; WORKFLOW;

EID: 84962602520     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515622827     Document Type: Review

References (43)

1. Compston A, Coles A., Multiple sclerosis. Lancet 2008; 372 (9648): 1502-1517, http://www.ncbi.nlm.nih.gov/pubmed/18970977 (. accessed 11 December 2013).
2. O'Connell K, Kelly SB, Fogarty E, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord 2014; 3 (6): 678-683, http://www.ncbi.nlm.nih.gov/pubmed/25891546 (. accessed 11 October 2015).
3. Adelman G, Rane SG, Villa KF., The cost burden of multiple sclerosis in the United States: A systematic review of the literature. J Med Econ 2013; 16 (5): 639-647, http://www.ncbi.nlm.nih.gov/pubmed/23425293 (. accessed 30 August 2015).
4. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013; 45 (11): 1353-1360, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3832895...tool=pmcentrez...rendertype=abstract (. accessed 18 March 2015).
5. Isobe N, Madireddy L, Khankhanian P, et al. An ImmunoChip study of multiple sclerosis risk in African Americans. Brain 2015; 138 (Pt 6): 1518-1530, http://www.ncbi.nlm.nih.gov/pubmed/25818868 (. accessed 11 October 2015).
6. Kroksveen AC, Jaffe JD, Aasebø E, et al. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics 2015; 15 (19): 3361-3369, http://www.ncbi.nlm.nih.gov/pubmed/26152395 (. accessed 11 October 2015).
7. Huynh JL, Garg P, Thin TH, et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci 2014; 17 (1): 121-130, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3934491...tool=pmcentrez...rendertype=abstract (. accessed 6 August 2015).
8. Duarte IF, Diaz SO, Gil AM., NMR metabolomics of human blood and urine in disease research. J Pharm Biomed Anal 2014; 93: 17-26, http://www.sciencedirect.com/science/article/pii/S0731708513004500 (. accessed 6 September 2015).
9. Scrivo R, Casadei L, Valerio M, et al. Metabolomics approach in allergic and rheumatic diseases. Curr Allergy Asthma Rep 2014; 14 (6): 445, http://www.ncbi.nlm.nih.gov/pubmed/24744271 (. accessed 6 September 2015).
10. Manna SK, Patterson AD, Yang Q, et al. UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the P para -null mouse model. J Proteome Res 2011; 10 (9): 4120-4133, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3170755...tool=pmcentrez...rendertype=abstract (. accessed 19 January 2014).
11. Blanchet L, Smolinska A, Attali A, et al. Fusion of metabolomics and proteomics data for biomarkers discovery: Case study on the experimental autoimmune encephalomyelitis. BMC Bioinformatics 2011; 12: 254, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3225201...tool=pmcentrez...rendertype=abstract (. accessed 6 September 2015).
12. Guo L, Milburn MV, Ryals JA, et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Sci 2015; 112 (35): E4901-E4910, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4568216...tool=pmcentrez...rendertype=abstract (. accessed 18 August 2015).
13. Sas KM, Karnovsky A, Michailidis G, et al. Metabolomics and diabetes: Analytical and computational approaches. Diabetes 2015; 64 (3): 718-732, http://diabetes.diabetesjournals.org.ezp.welch.jhmi.edu/content/64/3/718.long (. accessed 5 September 2015).
14. Dunn WB, Wilson ID, Nicholls AW, et al. The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis 2012; 4 (18): 2249-2264, http://www.ncbi.nlm.nih.gov/pubmed/23046267 (. accessed 14 October 2015).
15. Zamboni N, Saghatelian A, Patti GJ., Defining the metabolome: Size, flux, and regulation. Mol Cell 2015; 58 (4): 699-706, http://www.sciencedirect.com/science/article/pii/S1097276515003032 (. accessed 25 May 2015).
16. Want EJ, Wilson ID, Gika H, et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 2010; 5 (6): 1005-1018, http://dx.doi.org/10.1038/nprot.2010.50 (. accessed 24 July 2015).
17. Want EJ, Masson P, Michopoulos F, et al. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc 2013; 8 (1): 17-32, http://dx.doi.org/10.1038/nprot.2012.135 (. accessed 14 October 2015).
18. Smolinska A, Posma JM, Blanchet L, et al. Simultaneous analysis of plasma and CSF by NMR and hierarchical models fusion. Anal Bioanal Chem 2012; 403 (4): 947-959, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3336062...tool=pmcentrez...rendertype=abstract (. accessed 6 September 2015).
19. Alonso A, Marsal S, Julià A., Analytical methods in untargeted metabolomics: State of the art in 2015. Front Bioeng Biotechnol 2015; 3: 23, http://journal.frontiersin.org/article/10.3389/fbioe.2015.00023/abstract (. accessed 17 September 2015).
20. Cao MD, Lamichhane S, Lundgren S, et al. Metabolic characterization of triple negative breast cancer. BMC Cancer 2014; 14: 941, http://pmc/articles/PMC4295321/?report=abstract (. accessed 7 July 2015).
21. Smith CA, O'Maille G, Want EJ, et al. METLIN: A metabolite mass spectral database. Ther Drug Monit 2005; 27 (6): 747-751, http://www.ncbi.nlm.nih.gov/pubmed/16404815 (. accessed 22 September 2015).
22. Horai H, Arita M, Kanaya S, et al. MassBank: A public repository for sharing mass spectral data for life sciences. J Mass Spectrum 2010; 45 (7): 703-714, http://www.ncbi.nlm.nih.gov/pubmed/20623627 (. accessed 21 September 2015).
23. Benjamini Y, Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57 (1): 289-300, http://cat.inist.fr/?aModele=afficheN...cpsidt=3457006 (. accessed 15 October 2015).
24. Valcárcel B, Würtz P, Seich al, Basatena N-K, et al. A differential network approach to exploring differences between biological states: An application to prediabetes. PLoS ONE 2011; 6 (9): e24702, http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024702 (. accessed 15 October 2015).
25. Langfelder P, Horvath S., WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2631488...tool=pmcentrez...rendertype=abstract (. accessed 11 July 2014).
26. Demchak B, Hull T, Reich M, et al. Cytoscape: The network visualization tool for GenomeSpace workflows. F1000Res 2014; 3: 151, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4133763...tool=pmcentrez...rendertype=abstract (. accessed 15 October 2015).
27. Gao J, Tarcea VG, Karnovsky A, et al. Metscape: A Cytoscape plug-in for visualizing and interpreting metabolomic data in the context of human metabolic networks. Bioinformatics 2010; 26 (7): 971-973, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2844990...tool=pmcentrez...rendertype=abstract (. accessed 15 October 2015).
28. Rohn H, Junker A, Hartmann A, et al. VANTED v2: A framework for systems biology applications. BMC Syst Biol 2012; 6: 139, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3610154...tool=pmcentrez...rendertype=abstract (. accessed 8 October 2015).
29. Xia J, Sinelnikov IV, Han B, et al. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res 2015; 43 (W1): W251-W257, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4489235...tool=pmcentrez...rendertype=abstract (. accessed 21 April 2015).
30. Patel S, Ahmed S., Emerging field of metabolomics: Big promise for cancer biomarker identification and drug discovery. J Pharm Biomed Anal 2014; 107: 63-74, http://www.ncbi.nlm.nih.gov/pubmed/25569286 (. accessed 2 January 2015).
31. Noga MJ, Dane A, Shi S, et al. Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 2012; 8 (2): 253-263, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3291832...tool=pmcentrez...rendertype=abstract (. accessed 14 January 2014).
32. Mangalam A, Poisson L, Nemutlu E, et al. Profile of circulatory metabolites in a relapsing-remitting animal model of multiple sclerosis using global metabolomics. J Clin Cell Immunol 2013; 4, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3837296...tool=pmcentrez...rendertype=abstract (. accessed 30 December 2013).
33. 't Hart BA, Vogels JTWE, Spijksma G, et al. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci 2003; 212 (1-2): 21-30, http://www.ncbi.nlm.nih.gov/pubmed/12809995 (. accessed 23 September 2015).
34. Gebregiworgis T, Massilamany C, Gangaplara A, et al. Potential of urinary metabolites for diagnosing multiple sclerosis. ACS Chem Biol 2013; 8 (4): 684-690, http://www.ncbi.nlm.nih.gov/pubmed/23369377
35. Lynch J, Peeling J, Auty A, et al. Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can J Neurol Sci 1993; 20 (3): 194-198, http://www.ncbi.nlm.nih.gov/pubmed/8221382 (. accessed 24 September 2015).
36. Simone IL, Federico F, Trojano M, et al. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci 1996; 144 (1-2): 182-190, http://www.ncbi.nlm.nih.gov/pubmed/8994122 (. accessed 24 September 2015).
37. Aasly J, Gårseth M, Sonnewald U, et al. Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. Acta Neurol Scand 1997; 95 (1): 9-12, http://www.ncbi.nlm.nih.gov/pubmed/9048978 (. accessed 24 September 2015).
38. Sinclair AJ, Viant MR, Ball AK, et al. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases-A diagnostic tool? NMR Biomed 2010; 23 (2): 123-132, http://www.ncbi.nlm.nih.gov/pubmed/19691132 (. accessed 6 September 2015).
39. Reinke SN, Broadhurst DL, Sykes BD, et al. Metabolomic profiling in multiple sclerosis: Insights into biomarkers and pathogenesis. Mult Scler 2014; 20 (10): 1396-1400, http://www.ncbi.nlm.nih.gov/pubmed/24468817 (. accessed 26 August 2015).
40. Pieragostino D, D'Alessandro M, di Ioia M, et al. An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. Mol Biosyst 2015; 11 (6): 1563-1572, http://www.ncbi.nlm.nih.gov/pubmed/25690641 (. accessed 1 September 2015).
41. Dickens AM, Larkin JR, Griffin JL, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology 2014; 83 (17): 1492-1499, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4222850...tool=pmcentrez...rendertype=abstract (. accessed 6 September 2015).
42. Mehrpour M, Kyani A, Tafazzoli M, et al. A metabonomics investigation of multiple sclerosis by nuclear magnetic resonance. Magn Reson Chem 2013; 51 (2): 102-109, http://www.ncbi.nlm.nih.gov/pubmed/23255426 (. accessed 6 September 2015).
43. Moussallieh F-M, Elbayed K, Chanson JB, et al. Serum analysis by 1H nuclear magnetic resonance spectroscopy: A new tool for distinguishing neuromyelitis optica from multiple sclerosis. Mult Scler 2014; 20 (5): 558-565, http://www.ncbi.nlm.nih.gov/pubmed/24080986 (accessed 5 September 2015).